Trial articles

Ebola vaccine from Glaxo promising and safe
A 39-year-old woman has become the first volunteer to receive an experimental Ebola vaccine, which scientists have described as "promising".

New cholesterol drug alirocumab halved number of heart attacks and strokes
An experimental cholesterol-lowering drug from Sanofi and Regeneron Pharmaceuticals roughly halved the number of heart attacks and strokes in a clinical trial, revealed by researchers at the European Society of Cardiology yearly gathering in Barcelona.

Crohn's disease - accelerated step-care a best management practice
The final results from an international clinical trial involving nearly 2,000 patients with Crohn's disease support the use of a new management strategy referred to as accelerated step-care as a best practice for the care of active Crohn's disease.

Tongue controlled wheelchair better than sip and puff model
A new study shows that the wireless and wearable Tongue Drive System outperforms sip-and-puff in controlling wheelchairs. In the study, individuals with paralysis were able to use a tongue-controlled technology to access computers and execute commands for their wheelchairs at speeds that were significantly faster than those recorded in sip-and-puff wheelchairs, but with equal accuracy.

Mitral valve replacement may be more effective than mitral valve repair
The Cardiothoracic Surgical Trials Network (CTSN), whose Data and Clinical Coordinating Center is at Icahn School of Medicine at Mount Sinai, is reporting for the first time evidence on whether or not there is any significant difference between the two current surgical approaches to treat patients with severe ischemic mitral regurgitation -- mitral valve repair and mitral valve replacement.

Vedolizumab an effective treatment for Crohn's disease and ulcerative colitis
Investigational antibody vedolizumab is an effective treatment for those suffering from ulcerative colitis (UC) and Crohn's disease (CD) when other treatments have failed, revealed in an international clinical trial.

Urine test can diagnose and predict kidney transplant rejection
Analysis of three biomarkers in the urine of kidney transplant recipients can diagnose -- and even predict -- transplant rejection, according to results from a clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

Vitamin C can kill drug resistant tuberculosis bacteria
In a striking, unexpected discovery, researchers at Albert Einstein College of Medicine of Yeshiva University have determined that vitamin C kills drug-resistant tuberculosis (TB) bacteria in laboratory culture.

Alzheimer disease drug enters into phase II III study
Although several pharmaceutical companies in US have experienced setbacks with Alzheimer's compounds, Merck & Co., Inc. hopes to defy the odds with plans to take a Alzheimer pill into a Phase II/III clinical study with patients who suffer from mild-to-moderate stages of the Alzheimer's disease.

Multivitamins reduce risk of cancer in men
A daily multivitamin can help a man reduce his risk of cancer. The Physicians' Health Study II is the first clinical trial to test the affects of multivitamins on a major disease such as cancer.

Healthy diets have long lasting positive effects
Mediterranean and low-carbohydrate diets have lasting, healthy effects, even with partial weight regain. The study is published in a peer-reviewed letter in the current New England Journal of Medicine (NEJM) as an update to the landmark study, the workplace-based Dietary Intervention Randomized Controlled Trial (DIRECT), a tightly controlled 24-month dietary intervention.

Moderate alcohol consumption may increase atrial fibrillation risk
Moderate alcohol consumption increases the risk of atrial fibrillation in older people with heart disease or advanced diabetes, found a study in CMAJ. "Moderate to high alcohol intake was associated with an increased incidence of atrial fibrillation among people aged 55 or older with cardiovascular disease or diabetes," writes Dr. Koon Teo, McMaster University, Hamilton, Ontario, with coauthors.

Acupuncture may be better for chronic pain
An analysis of patient data from 29 randomized controlled trials suggests that acupuncture may be better than no acupuncture or sham acupuncture for the treatment of some chronic pain.

Polypill reduces heart attack and stroke risks
Results of a randomised trial carried out by academics at Queen Mary, University of London show that a four-component Polypill given to people aged 50 and over to reduce their risk of heart attack and stroke, the most common causes of death worldwide, achieved large reductions in blood cholesterol and blood pressure, the main causes of these two diseases.

Alzheimer's Disease timeline invaluable for successful drug trials
Scientists have assembled the most detailed chronology to date of the human brain's long, slow slide into full-blown Alzheimer's disease. As part of an international research partnership known as the Dominantly Inherited Alzheimer's Network (DIAN), scientists at Washington University and elsewhere evaluated a variety of pre-symptomatic markers of Alzheimer's disease in 128 subjects from families genetically predisposed to develop the disorder.

Cholesterol lowering statins reduce heart diseases and cardiovascular events
Cholesterol-lowering statin drugs appear to be associated with reduced risk of recurrent cardiovascular events in men and women, but do not appear to be associated with reduced all-cause mortality or stroke in women. Statins have been used to lower cholesterol levels for the last 20 years.

Stroke risk greater for older women with atrial fibrillation
In a study that examined use of the anticoagulant medication warfarin and risk of stroke following a diagnosis of atrial fibrillation in older patients, women, especially those 75 years or older, had a higher risk of stroke than men, regardless of their risk profile and use of warfarin, suggesting that current anticoagulant therapy to prevent stroke might not be sufficient for older women.

Brain cancer vaccine prepared from brain tumor proves effective
A new brain cancer vaccine tailored to individual patients by using material from their own tumors has proven effective in a multicenter phase 2 clinical trial at extending their lives by several months or longer. The patients suffered from recurrent glioblastoma multiforme-which kills thousands of Americans every year.

Heart failure patients may get benefit from testosterone supplements
Testosterone supplements helped heart failure patients breathe better and exercise more. This new research analyzed four randomized clinical trials of patients with moderate to severe chronic heart failure. Patients were given commercial testosterone supplements by injection, patch or gel.

Bariatric surgery improves and reverses diabetes
Overweight, diabetic patients who underwent bariatric surgery achieved significant improvement or remission of their diabetes.In a randomized, controlled trial, some weight loss surgery patients achieved normal blood sugar levels without use of any diabetes medications.

Alzheimer's Disease patients may not get benefit from antioxidants
An antioxidant combination of vitamin E, vitamin C and a-lipoic acid (E/C/ALA) was not associated with changes in some cerebrospinal fluid biomarkers related to Alzheimer disease in a randomized controlled trial, revealed by researchers.

New technique for screening breast cancer using ultrasound
Scientists have successfully completed an initial trial of a new, potentially more reliable, technique for screening breast cancer using ultrasound. The team at the National Physical Laboratory (NPL), the UK's National Measurement Institute, working with the University Hospitals Bristol NHS Foundation Trust, are now looking to develop the technique into a clinical device.

CT colonography a front line colorectal cancer screening tool for seniors
Computerized tomographic (CT) colonography (CTC), also known as virtual colonoscopy, is comparable to standard colonoscopy in its ability to accurately detect cancer and precancerous polyps in people ages 65 and older.

Regorafenib improves survival of colorectal cancer patients
Regorafenib - an investigational drug - slowed the progression of tumors and lengthened the lives of patients with metastatic colorectal cancer. This is the first novel agent in eight years to show improvement in overall survival of colon cancer patients who have run out of treatment options.

New cancer drug development institute at UT MD Anderson
Academic and government leaders announced the establishment of a major new research institute at The University of Texas MD Anderson Cancer Center that will blend the best attributes of academic and industrial research to identify and validate new cancer targets, convert such scientific knowledge into new cancer drugs, and advance these novel agents into innovative clinical trials.

Transcatheter aortic valve replacement TAVR shows superiority in heart patients
A two-year study of patients in the landmark PARTNER trial, which compared transcatheter aortic valve replacement (TAVR) in patients who have severe aortic stenosis and are not candidates for open heart surgery, confirm the one-year findings and support the role of TAVR as the standard of care.

CCSVI role in multiple sclerosis seems to be controversial
Chronic cerebrospinal venous insufficiency (CCSVI) appears to be more common in people with multiple sclerosis than in people without the condition, states a review of published studies in CMAJ (Canadian Medical Association Journal).However, there are not enough high-quality studies to allow definitive conclusions.

Hormonal contraception doubles HIV risk in Africa
Women using hormonal contraception -- such as a birth control pill or a shot like Depo-Provera ? are at double the risk of acquiring HIV, and HIV-infected women who use hormonal contraception have twice the risk of transmitting the virus to their HIV-uninfected male partners.

Expandable prosthesis resolves advanced aortic valve disease
Among individuals 65 years and older, as many as 30 percent have aortic valve sclerosis or stenosis and as a result of their deteriorating health, they cannot enjoy a normal lifestyle.

Alpharadin improved survival in advanced prostate cancer patients
Until recently, options for patients with bone metastases from advanced prostate cancer have been very limited. But now the first Phase III study of an alpha-pharmaceutical in these patients has shown that it can prolong survival significantly, according to research reported recently at the 2011 European Multidisciplinary Cancer Congress.

Stroke clinical trial finds intensive medical treatment better than brain stent
Patients at a high risk for a second stroke who received intensive medical treatment had fewer strokes and deaths than patients who received a brain stent in addition to the medical treatment, a large nationwide clinical trial has shown.

Rivaroxaban can prevent strokes in atrial fibrillation patients
Rivaroxaban, an anti-clotting drug, was shown to be an attractive alternative to warfarin in the prevention of stroke in patients with atrial fibrillation, revealed by researchers recently.

Massage therapy helps ease chronic low back pain
The hour-long massage treatments (structural and relaxation massage) help people with back pain to function even after six months, reported in a new research. People who have persistent back pain may want to consider massage as an option.

20% reduction in lung cancer mortality with low dose CT vs chest X ray
Scientists have found a 20 percent reduction in deaths from lung cancer among current or former heavy smokers who were screened with low-dose helical computed tomography (CT) versus those screened by chest X-ray. The primary research results from the National Lung Screening Trial (NLST) were published in the New England Journal of Medicine.

FDA panel votes to revoke approval for Avastin for advanced breast cancer
The Oncologic Drugs Advisory Committee, FDA, USA disapproved the Avastin which cited a lack of survival benefit. Now as two more trials have been analyzed -- neither showing a survival benefit -- the FDA stated that in the balance, the benefit did not outweigh the harm.

Abatacept and GAD-alum to slow progression of type 1 diabetes
Abatacept (Orencia), an immune system modulator and GAD-alum, an antigen based therapy found beneficial for patients with type 1 diabetes. TrialNet researchers are conducting a series of studies to test ways to prevent or delay progression of type 1 diabetes. Results of two studies testing drugs to slow or stop the immune system's attack on insulin-producing cells in people newly diagnosed with type 1 diabetes will be presented at the American Diabetes Association's (ADA) 71st Scientific Sessions in San Diego and simultaneously published online in the Lancet.

Lithium may prevent brain damage in patients with Parkinson's disease
Researcher are focusing on lithium as a potential treatment for Parkinson's disease -- PD -- as well as its efficacy in combination with drugs currently used to control the symptoms of the disease. Lithium profoundly prevents the aggregation of toxic proteins and cell loss associated with Parkinson's disease (PD) in a mouse model of the condition.

Ovarian cancer screening does not improve survival
In a clinical trial that included nearly 80,000 women, those who received ovarian cancer screening did not have a reduced risk of death from ovarian cancer compared to women who received usual care, but did have an increase in invasive medical procedures and associated harms as a result of being screened.

Pfizer drug reduces breast cancer in high risk women
The drug exemestane significantly reduces the risk of breast cancer in high-risk, postmenopausal women is the result of an international, randomized double-blind phase III clinical trial in which University at Buffalo researchers and hundreds of Western New York women played a critical role, revealed at the American Society of Clinical Oncology annual meeting.

Niacin and statin treatment did not protect heart
The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has stopped a clinical trial studying a blood lipid treatment 18 months earlier than planned.

New class of cancer drugs could work in colon cancers with genetic mutation
A class of drugs that shows promise in breast and ovarian cancers with BRCA gene mutations could potentially benefit colorectal cancer patients with a different genetic mutation, a new study from the University of Michigan Comprehensive Cancer Center finds.

Stem cells repair heart damage in a human trial
Researchers have shown for the first time that stem cells injected into enlarged hearts reduced heart size, reduced scar tissue and improved function to injured heart areas, according to a small trial published in Circulation Research: Journal of the American Heart Association.

Omalizumab relieves seasonal asthma attacks in youth
A drug that targets the antibody immunoglobulin E (IgE), a key player in asthma, nearly eliminated seasonal increases in asthma attacks and decreased asthma symptoms among young people living in inner city environments, a clinical trial sponsored by the National Institutes of Health has found.

Stroke survivors with irregular heartbeat may have higher risk of dementia
Stroke survivors who have an irregular heartbeat called atrial fibrillation may be at higher risk of developing dementia than stroke survivors who do not have the heart condition, according to research published in the March 8, 2011, print issue of Neurology?, the medical journal of the American Academy of Neurology.

Fetal surgery better in treating children with spina bifida
Thirty years ago, the first human fetal surgery was performed at the University of California, San Francisco. Now, a randomized controlled trial has proven definitively that fetal surgery can help certain patients before birth.

New drug for melanoma skin cancer patients soon
Plexxikon Inc. announced positive data from an interim analysis of the BRIM3 trial, a large multi-center Phase 3 clinical study of PLX4032 (RG7204) in patients with previously untreated metastatic melanoma with the BRAF mutation.

International clinical trial tests targeted drug for melanoma skin cancer
Rush University Medical Center has just enrolled the first U.S. patient in an international clinical trial testing a novel drug to treat certain kinds of melanoma, a deadly skin cancer that in its advanced stages currently has few effective treatments.

US company starts clinical trial using stem cells to treat macular degeneration
Advanced Cell Technology, Inc. ("ACT"; OTCBB:ACTC) announced that the US Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to immediately initiate a Phase I/II multicenter clinical trial using retinal cells derived from human embryonic stem cells (hESCs) to treat patients with Stargardt's Macular Dystrophy (SMD), one of the most common forms of juvenile macular degeneration in the world.

Clinical trial of human embryonic stem cell therapy in US
Geron Corporation (Nasdaq: GERN) announced the enrollment of the first patient in the company's clinical trial of human embryonic stem cell (hESC)-derived oligodendrocyte progenitor cells, GRNOPC1.

Genetic patterns may predict osteoarthritis
Scientists from University of North Carolina at Chapel Hill School of Medicine and Interleukin Genetics, Inc. announced findings from a large clinical study to evaluate the role played by genetic factors in the worsening of osteoarthritis.

Avandia use is restricted for diabetes patients
FDA will restrict the use of the diabetes drug Avandia (rosiglitazone) to patients with Type 2 diabetes who cannot control their diabetes on other medications. Avandia may elevate risk of cardiovascular events, such as heart attack and stroke.

Initial trials on new ovarian cancer tests exhibit extremely high accuracy
Scientists at the Georgia Institute of Technology have attained very promising results on their initial investigations of a new test for ovarian cancer. Using a new technique involving mass spectrometry of a single drop of blood serum, the test correctly identified women with ovarian cancer in 100 percent of the patients tested. The results can be found online in the journal Cancer Epidemiology, Biomarkers, & Prevention Research.

Ipilimumab demonstrates improved survival in metastatic melanoma
Bristol-Myers Squibb Company (NYSE: BMY) announced positive results from a Phase 3 randomized, double blind study of ipilimumab which demonstrated that overall survival (OS) was significantly extended in patients with previously-treated metastatic melanoma who received ipilimumab.

Education of clinicians improves prescribing for high blood pressure patients
Academic detailing-a method involving face-to-face education of clinicians by investigators trained to present trial findings and guidelines-may have been associated with a small change in prescribing patterns for patients with high blood pressure, according to a report in the May 24 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

Pregnancy doubles HIV risk in men
A new study finds that pregnancy is a time when men are at greater risk. In fact, their risk doubles if their partner is both HIV-infected and pregnant.

Ablation heart procedure reduces risk of Alzheimer and stroke
Researchers found that ablation treatment can eliminate serious risks associated with atrial fibrillation. New research was presented at National Heart Rhythm Society.

Eating nuts improve blood cholesterol levels
Consuming more nuts appears to be associated with improvements in blood cholesterol levels, according to a pooled analysis of data from 25 trials reported in the May 10 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

Artificial pancreas successfully controls blood sugar more than 24 hours
An artificial pancreas system that closely mimics the body's blood sugar control mechanism was able to maintain near-normal glucose levels without causing hypoglycemia in a small group of patients.

Choosing VBAC or plan a repeat cesarean delivery
An independent panel convened this week by the National Institutes of Health confronted a troubling fact that pregnant women currently have limited access to clinicians and facilities able and willing to offer a trial of labor after previous cesarean delivery because of so-called VBAC bans.

Pneumococcal vaccine offers protection to HIV infected
A clinical trial of a vaccine against a major cause of pneumonia and meningitis has shown that it can prevent three out of four cases of re-infection in HIV-infected adults in Africa.

Ethosuximide is preferred for childhood epilepsy
The first comprehensive comparative effectiveness clinical trial of three widely used anti-seizure drugs for childhood absence epilepsy ? the most common form of epilepsy in kids ? has established an evidence-based approach for initial drug therapy.

Progesterone for traumatic brain injury tested
Researchers at 17 medical centers across the US soon will begin using the hormone progesterone to treat patients who experience traumatic brain injury (TBI).

New safety controls for asthma drugs, US
The U.S. Food and Drug Administration announced that drugs in the class of long-acting beta agonists (LABAs) should never be used alone in the treatment of asthma in children or adults.

Catheter treatment works better than drugs for heart rhythm disorder
Treating a common heart rhythm disorder by burning heart tissue with a catheter works dramatically better than drug treatments, according to a landmark study published in the Jan. 27 issue of the Journal of the American Medical Association (JAMA).

Testing gene therapy for Alzheimer's disease
University Hospitals Case Medical Center is one of 12 sites conducting the first Phase 2 clinical trial of a gene therapy for Alzheimer's disease (AD). The study uses a viral-based gene transfer system called CERE-110, which is designed to deliver nerve growth factor (NGF) into the brain.

PRO 2000 anti HIV gel is ineffective
Pro 2000, a vaginal microbicide gel designed to reduce women's risk of HIV infection, showed no evidence that it reduces the risk of HIV infection, revealed by researchers at Britain's Medical Research Council (MRC).

Human Genome Sequencing decoded in India
The Council of Scientific and Industrial Research (CSIR) has achieved completion of first ever Human Genome Sequencing in India. Scientist of CSIR at the Institute of Genomics and Integrative Biology (IGIB), Delhi have sequenced the Human Genome of an anonymous healthy Indian citizen.

New 3 drug combination for multiple myeloma patients
A new three-drug combination has shown in a phase 1/2 clinical trial that it is a "highly effective regimen" in the treatment of patients newly diagnosed with multiple myeloma, a cancer of white blood cells in bone marrow, say researchers from Dana-Farber Cancer Institute.

Vioxx trial data shows early heart risk
US researchers revealed that the heart complications after taking Vioxx, the nonsteroidal anti-inflammatory drug (rofecoxib), could have been identified nearly four years before its manufacturer Merck pulled the drug from the market.

New HIV vaccine safe and effective in preventing HIV infection
In an encouraging development, an investigational vaccine regimen has been shown to be well-tolerated and to have a modest effect in preventing HIV infection in a clinical trial involving more than 16,000 adult participants in Thailand.

New treatment for melanoma shows shrinking of tumors
Researchers have made significant advances in the treatment of metastatic malignant melanoma ? one of the most difficult cancers to treat successfully once it has started to spread.

Gene therapy may cure Alzheimer's disease
To stop the progression of Alzheimer's disease, scientists are conducting gene therapy trial on patients with a mild form of Alzheimer's Disease in US.

2009 H1N1 influenza vaccines in healthy adults - early results
There are encouraging reports emerging from various clinical trials of 2009 H1N1 influenza vaccines, conducted by various vaccine manufacturers. Additional companies are expected to announce their preliminary trial results shortly.

A new therapy to cure skin cancer
A potential new investigational therapy for advanced and metastatic basal cell skin cancer is revealed by researchers.

Anticoagulant Dabigatran effective in atrial fibrillation patients
The anticoagulant dabigatran is more effective than warfarin in the prevention of stroke in patients with atrial fibrillation, revealed by researchers in a study RE-LY (Randomized Evaluation of Long-term anticoagulant therapY).

Mediterranean diet and exercise lower Alzheimer's disease risk
Both being more physically active and adhering to a Mediterranean-type diet appears to be associated with reduced Alzheimer's risk, according to a new report in the August 12, 2009 issue of the Journal of the American Medical Association (JAMA).

Swine flu vaccine trials under way, UK
UK's first swine flu vaccine trials, led by the University of Leicester and University Hospitals of Leicester NHS Trust, are taking place at the Leicester Royal Infirmary.

US to launch clinical trials to test 2009 H1N1 influenza vaccine
Scientists in a network of medical research institutions across the United States are set to begin a series of clinical trials to gather critical data about influenza vaccines, including two candidate H1N1 flu vaccines.

Orexigen's Contrave trials successful for obesity treatment
Orexigen Therapeutics, Inc. (Nasdaq: OREX) announced that all three remaining Phase 3 trials evaluating Contrave(R) (bupropion SR/naltrexone SR), its investigational drug for the treatment of obesity, met their co-primary endpoints.

Lupus drug Benlysta effective for SLE patients
Human Genome Sciences, Inc. (Nasdaq: HGSI) and GlaxoSmithKline PLC (GSK) announced that BENLYSTA (belimumab, formerly LymphoStat-B?) met the primary endpoint in BLISS-52, the first of two pivotal Phase 3 trials in patients with serologically active systemic lupus erythematosus (SLE).

Breast cancer drug Abraxane promising for malignant melanoma treatment
An approved breast-cancer drug nab-paclitaxel, trade named Abraxane, has been found promising in clinical trial for the treatment of metastatic malignant melanoma, revealed by researchers.

New consensus on using APBI to treat breast cancer
A new consensus statement outlining patient selection criteria and best practices for the use of accelerated partial breast irradiation (APBI) outside the context of a clinical trial has been published in the July 15 issue of the International Journal of Radiation Oncology Biology Physics.

Prostate cancer risk from heavy drinking
In a new study, researchers examined the associations of total alcohol, type of alcoholic beverage, and drinking pattern with risks of total, low- and high-grade prostate cancer.

Sanofi's Multaq approved to treat heart rhythm disorder, US
The U.S. Food and Drug Administration has approved Sanofi's Multaq tablets (dronedarone) to help maintain normal heart rhythms in patients with a history of atrial fibrillation or atrial flutter (heart rhythm disorders or arrhythmia).

Takeda's diabetes drug alogliptin received FDA's objection
US top most health agency FDA has asked Takeda to conduct an additional clinical trial to rule out any adverse effects of alogliptin in relation to heart, that means Takeda needs to conduct a cardiovascular safety trial for alogliptin.

Prostate cancer screening may result in overdiagnosis of cancer
The recent release of two large randomized trials suggests that if there is a benefit of screening, it is, at best, small, says a new report in CA: A Cancer Journal for Clinicians.

Rheumatoid arthritis drug masitinib found effective
A clinical trial of masitinib, a drug in development for the treatment of rheumatoid arthritis, has shown it to be well tolerated and effective, revealed by researchers in BioMed Central's journal Arthritis Research and Therapy.

Success with ipilimumab in prostate cancer patients
Two Mayo Clinic patients whose prostate cancer had been considered inoperable are now cancer free thanks in part to an experimental drug therapy that was used in combination with standardized hormone treatment and radiation therapy.

Option Inferior Vena Cava Filter gets FDA clearance in US
Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Option(TM) Inferior Vena Cava (IVC) Filter in the United States, for use in both permanent and retrievable indications.

Avandia has no increased overall heart risk
Clinical trial results presented at the American Diabetes Association annual meeting show that overall rates of cardiovascular hospitalization and cardiovascular death are similar in patients taking Avandia (rosiglitazone) compared to those receiving metformin and sulfonylurea.

Merck's heart failure drug rolofylline failed
Merck's experimental heart failure drug rolofylline failed to meet the goals in a clinical trial, failing to improve patients. Merck won't seek approval this year for this heart failure drug rolofylline after preliminary results.

Positive clinical trial results of vilazodone for depression
Clinical Data, Inc. (NASDAQ: CLDA) announced positive top-line results from the second of two Phase III trials of its investigational compound, vilazodone, for the treatment of major depressive disorder (MDD).

Breast cancer gene responds to blood pressure drug in lab
Researchers have identified a gene that is overexpressed in up to 20 percent of breast cancers and that could be blocked in the lab by a currently available blood pressure drug, according to a new study from the University of Michigan Comprehensive Cancer Center.

Vandetanib with docetaxel improve lung cancer survival
When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, according to research from The University of Texas M. D. Anderson Cancer Center.

Green tea shows promise in leukemia
Mayo Clinic researchers are reporting positive results in early leukemia clinical trials using the chemical epigallocatechin gallate (EGCG), an active ingredient in green tea.

$24 million for rare and neglected diseases research
The National Institutes of Health is launching the first integrated, drug development pipeline to produce new treatments for rare and neglected diseases. The $24 million program jumpstarts a trans-NIH initiative called the Therapeutics for Rare and Neglected Diseases Program, or TRND.

AIDS patients get benefit from early retroviral use
HIV-positive patients who don't seek medical attention until they have a serious AIDS-related condition can reduce their risk of death or other complications by half if they get antiretroviral treatment early on, according to a new multicenter trial led by researchers at the Stanford University School of Medicine.

Heart disorder linked to Alzheimer's disease dementia
Researchers at Intermountain Medical Center in Salt Lake City believe that they have made a breakthrough connection between atrial fibrillation, a fairly common heart rhythm disorder, and Alzheimer's disease, the leading form of dementia among Americans.

Champion clinical trial program of cangrelor discontinued
The Medicines Company (NASDAQ: MDCO) announced that it is discontinuing its Phase 3 CHAMPION clinical trial program of cangrelor in patients undergoing percutaneous coronary intervention (PCI).

Acupuncture eases chronic low back pain in SPINE trial
Acupuncture can help people with chronic low back pain feel less bothered by their symptoms and function better in their daily activities, according to the largest randomized trial of its kind, published in the May 11, 2009 Archives of Internal Medicine.

Herpes medication does not reduce HIV transmission risk
A recently completed international multi-center clinical trial has found that acyclovir, a drug widely used as a safe and effective treatment to suppress herpes simplex virus-2 (HSV-2), which is the most common cause of genital herpes, does not reduce the risk of HIV transmission when taken by people infected with both HIV and HSV-2.

New drug aims to transform malaria treatment
Ranbaxy Laboratories Limited (Ranbaxy) announced the commencement of Phase-III clinical trials for its new Anti-malaria combination drug, Arterolane maleate + Piperaquine phosphate in India, Bangladesh and Thailand.

Anti aging cosmetic reduces wrinkles
Scientists testing a cosmetic anti-ageing product sold on the high street have shown it can clinically reduce wrinkles and improve the appearance of skin damaged by everyday exposure to sunlight.

Prostate cancer immunotherapy prolongs survival
Sipuleucel-T (Provenge), an experimental immunotherapy improved survival in men with metastatic disease, according to new results to be presented April 28 at the American Urological Association (AUA) Annual Scientific Meeting in Chicago.

Boosting immune response to destroy tumours
Researchers have discovered how to trigger an improved immune response to cancer that could be included in new clinical trials that use a patient's own cells to destroy tumours.

New iPhone app allows search of all registered clinical trials
Before today, searching for one of more than 71,500 clinical trials in the National Library of Medicine and National Institutes of Health database required a chair, computer, internet connection, and a session on the government's clinical trials website.

Male circumcision surely reduces HIV risk
Three recent African trials support male circumcision for reducing the risk of contracting HIV in heterosexual men.

Plavix reduced major vascular events by 11% in heart disease
Plavix plus aspirin more effective than aspirin alone in preventing major vascular events in patients with atrial fibrillation who cannot take oral anticoagulants.

Positive results of Albuferon in Chronic Hepatitis C
Human Genome Sciences, Inc. (Nasdaq: HGSI) announced that Albuferon (albinterferon alfa-2b) met its primary endpoint of non-inferiority to peginterferon alfa-2a (Pegasys) in ACHIEVE 1, a Phase 3 clinical trial of Albuferon in combination with ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C (p=0.0008).

Microbicide promising as HIV prevention method for women
A clinical trial involving more than 3,000 women in the U.S. and southern Africa demonstrates for the first time the promise of a vaginal microbicide gel for preventing HIV infection in women.

Advice for treatment of cough, colds in children under 6
Responding to guidance issued by the Medicines and Healthcare products Regulatory Agency (MHRA), advising that cough and cold treatments should not be used for children under 6 years of age, the Royal Pharmaceutical Society of Great Britain (RPSGB) has issued the following advice to parents.

Clinical trials overseas raises quality control issues
Top-tier U.S.-based pharmaceutical companies are moving their clinical trials overseas at warp speed, raising questions about ethics, quality control, and even the scientific value of their findings for people back in the U.S.

Multivitamins offer no benefit in postmenopausal women
The largest study ever conducted on postmenopausal women shows that multivitamins may offer no benefit in reducing the risk of common cancers, cardiovascular disease or overall mortality.

ViroPharma's Maribavir failed in bone marrow transplant patients
ViroPharma Incorporated (Nasdaq: VPHM) announced that its Phase 3 trial evaluating maribavir used as prophylaxis in allogeneic stem cell, or bone marrow, transplant (SCT) patients did not achieve its primary endpoint.

Anti HIV gel shows promise in preventing HIV infection in women
An investigational vaginal gel intended to prevent HIV infection in women has demonstrated encouraging signs of success in a clinical trial conducted in Africa and the United States.

Weight loss reduces urinary incontinence in overweight obese women
Reducing urinary incontinence can now be added to the extensive list of health benefits of weight loss, according to a clinical trial funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the Office of Research on Women's Health (ORWH), both part of the National Institutes of Health (NIH).

Human clinical trial of embryonic stem cell therapy approved
Geron Corporation (Nasdaq: GERN) announced that the U.S. Food and Drug Administration (FDA) has granted clearance of the company's Investigational New Drug (IND) application for the clinical trial of GRNOPC1 in patients with acute spinal cord injury.

Postnatal depression can be prevented
Health visitors can be trained to identify women with postnatal depression and offer effective treatment, while telephone peer support (mother to mother) may halve the risk of developing postnatal depression, suggests research published on

Vitamins C and E and beta carotene may not reduce cancer risk
Women who took beta carotene or vitamin C or E or a combination of the supplements had a similar risk of cancer as women who did not take the supplements, according to data from a randomized controlled trial in the December 30 online issue of the Journal of the National Cancer Institute.

Healthy diet may cut risk of breast cancer recurrence
A secondary analysis of a large, multicenter clinical trial has shown that a diet loaded with fruits, vegetables and fiber and somewhat lower in fat compared to standard federal dietary recommendations cuts the risk of recurrence in a subgroup of early-stage breast cancer survivors ? women who didn't have hot flashes ? by approximately 31 percent.

Hepatitis C declines health with liver disease
An NIH funded multi-center clinical trial found no benefit from "maintenance therapy," low-dose peginterferon used for hepatitis C patients who have not responded to an initial round of treatment.

New drug tasimelteon for jet lag
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) reports publication in The Lancet, one of the world's leading medical journals, results of clinical trials of its novel circadian regulator, experimental compound tasimelteon (VEC-162).

Ginkgo biloba does not reduce dementia, Alzheimer's disease risk
The medicinal herb Ginkgo biloba does not reduce the risk of dementia or Alzheimer's disease development in either the healthy elderly or those with mild cognitive impairment, according to a large multicenter trial led by researchers at the University of Pittsburgh School of Medicine.

Single PILL may prevent heart disease
A new clinical trial looking at a single pill to prevent cardiovascular disease is starting in Auckland, New Zealand.

Calcium, vitamin D may not reduce breast cancer risk
Taking calcium and vitamin D supplements does not reduce breast cancer incidence in postmenopausal women, according to data from a randomized, doubled-blind, placebo-controlled trial published online November 11 in the Journal of the National Cancer Institute.

Acomplia rimonabant obesity drug withdrawn
Sanofi-aventis announced that the European Medicines Agency (EMEA) has recommended to the European Commission (EC) the temporary suspension of the marketing authorisation of Acomplia(R) (rimonabant) for the approved indication of overweight and obese patients.

Live cell therapy clinical trial in New Zealand for diabetics
Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) announced that New Zealand Health Minister, the Honorable David Cunliffe, has approved an application from the company to conduct in New Zealand a Phase I/IIa clinical trial of DiabeCell?, LCT's lead product candidate for the treatment of insulin dependent (Type 1) diabetes.

Vitamin B does not slow cognitive decline in Alzheimer's disease
A clinical trial led by Paul S. Aisen, M.D., professor of neurosciences at the University of California, San Diego School of Medicine, showed that high-dose vitamin B supplements did not slow the rate of cognitive decline in patients with mild to moderate Alzheimer disease.

Trials supporting FDA approved drugs remained unpublished
Over half of all supporting trials for FDA-approved drugs remained unpublished 5 years after approval, says new research published in this week's PLoS Medicine. The most important trials determining efficacy, and those with statistically significant results and larger sample sizes, are more likely to be published.

India to develop HIV AIDS vaccine soon
A second Phase I AIDS vaccine clinical trial in India was successfully completed, the Indian Council of Medical Research, the National AIDS Control Organization and the International AIDS Vaccine Initiative announced.

Keeping a food diary doubles weight loss
Keeping a food diary can double a person's weight loss according to a study from Kaiser Permanente's Center for Health Research. The findings, from one of the largest and longest running weight loss maintenance trials ever conducted, will be published in the August issue of the American Journal of Preventive Medicine.

Bapineuzumab promising in treating Alzheimer's disease
Elan Corporation, plc (NYSE: ELN) and Wyeth (NYSE: WYE) announced encouraging preliminary findings from a Phase 2 study of bapineuzumab (AAB-001) in patients with mild to moderate Alzheimer's disease. In the 18-month trial, bapineuzumab appeared to have clinical activity in treating Alzheimer's disease.

Prasugrel cuts risk of stent-related clots
The investigational antiplatelet drug prasugrel plus aspirin produced a marked and highly statistically significant reduction in the risk of coronary stent thrombosis (ST) - a major concern for physicians and patients with potentially fatal consequences - in patients who received a stent as compared to standard therapy with clopidogrel (Plavix) plus aspirin, according to a stent analysis from the head-to-head TRITON-TIMI 38 trial.

VereFlu portable lab-on-chip for detection of bird flu
Following the success of the evaluation trials conducted at the prestigious National University Hospital of Singapore, Veredus Laboratories and STMicroelectronics (NYSE: STM) announced the commercial availability of VereFlu, a portable lab-on-chip application for rapid detection of all major influenza types at the point of need.

GSK statement on MHRA Seroxat investigation
GlaxoSmithKline (GSK) notes the conclusions announced by the Medicines and Healthcare products Regulatory Agency (MHRA) regarding its investigation into disclosure of paediatric trial data for the anti-depressant medicine Seroxat (paroxetine).

Clot busting treatment effective if given in 6 hours after a stroke
The study, co-ordinated by the Royal Melbourne Hospital and conducted by the Australasian Stroke Trialists Network including the Hunter Medical Research Institute (HMRI) Stroke Research Group demonstrates that clot busting (thrombolysis) treatment can be effective when administered up to six hours after a stroke.

Tenofovir gel safe for daily use
A vag inal microbicide that incorporates an antiretroviral (ARV) drug normally used to treat people with HIV is safe for sexually active HIV-negative women to use every day over an extended period, suggest results of a clinical trial of tenofovir topical gel.

Antidepressant and psychotherapy work for depressed teens
Teens with difficult-to-treat depression who do not respond to a first antidepressant medication are more likely to get well if they switch to another antidepressant medication and add psychotherapy rather than just switching to another antidepressant, according to a large, multi-site trial funded by the National Institutes of Health's National Institute of Mental Health (NIMH).

Cholesterol drug statins may reduce heart's atrial fibrillation
When we're young, a racing heart often means love is in the air. If you're a "baby boomer," it might mean you've just joined the 2.2 million Americans who have atrial fibrillation (AF), an irregularity in the heart's rhythm that grows more common as we age and markedly increases the risk for stroke.

Stem cell therapy trials to mend shattered bones
Scientists are developing a revolutionary way to mend damaged bones and cartilage using a patient's own stem cells.

Glucosamine no better than placebo in reducing hip pain
A new, two-year, randomized, placebo-controlled trial found that glucosamine sulfate was no better than placebo in controlling hip pain, the ability to do normal activities and the progression of hip osteoarthritis. Glucosamine is a natural substance found in healthy joint cartilage.

Laser to detect potential diseases via breath
By blasting a person's breath with laser light, scientists from the National Institute of Standards and Technology and the University of Colorado at Boulder have shown that they can detect molecules that may be markers for diseases like asthma or cancer.

Cholesterol lowering drug may fight staph infection
An international team of researchers supported by the National Institutes of Health (NIH) has blocked staph infections in mice using a drug previously tested in clinical trials as a cholesterol-lowering agent. The novel approach, described in the February 14 online edition of Science, could offer a new direction for therapies against a bacterium that's becoming increasingly resistant to antibiotics.

$9 million grant for prostate cancer research
Henry Ford Hospital is embarking on an expanded major clinical trial involving the use of gene therapy in combination with radiation therapy, to determine if the combined treatment is more effective than radiation therapy alone for patients with intermediate risk prostate cancer.

Intensive blood glucose lowering treatment proved fatal for diabetes patients
Intensive blood glucose lowering treatment proved fatal for diabetes patients in a US study, and for Safety, National Heart, Lung, and Blood Institute (NHLBI) has changed intensive blood sugar treatment strategy in clinical trial of diabetes and cardiovascular disease.

Ongoing review of cholesterol drug Vytorin
The U.S. Food and Drug Administration (FDA) is informing the public that the agency will conduct a review of Merck and Schering Plough's recent trial once the FDA receives the final study results.

Vytorin does not appear to be unsafe - American Heart Association
Merck/Schering-Plough Pharmaceuticals released results from the ENHANCE trial, which found that the ezetimibe/simvastatin (Zetia/Zocor) combination drug known as Vytorin was no more effective in reducing artery plaque build-up than simvastatin (Zocor) alone. There were no statistically significant differences in the safety of the drugs, which are used to lower cholesterol.

NEJM Antidepressant's Publication study may discourage depressed people
Mental Health America notifies the potential harm of the NEJM's Selective Publication of Antidepressant Trials study that it may discourage people with depression from seeking appropriate care and evidence-based treatments that work for them. Mental Health America is one of America's leading mental health advocacy groups.

GVAX cancer immunotherapy improves prostate cancer survival
Cell Genesys, Inc. (Nasdaq: CEGE) announced that the Independent Data Monitoring Committee (IDMC) for VITAL-1, the first of two ongoing Phase 3 clinical trials of GVAX immunotherapy for prostate cancer, has completed a pre-planned interim analysis and has recommended that the study continue, as GVAX cancer immunotherapy improves prostate cancer patients survival.

Selective reporting of antidepressant trials may have adverse consequences
Selective publication in reporting results of antidepressant trials exaggerates the effectiveness of the drugs, and may have adverse consequences for researchers, study participants, health care professionals, and patients, revealed in a new study.

American physicians prescribe placebos on occasion
In the first study examining American physicians' use of placebos in clinical practice in the 21st Century, 45 percent of Chicago internists report they have used a placebo at some time during their clinical practice researchers report in the January issue of Journal of General Internal Medicine.

Potential drugs for mental retardation and autism treatment
Researchers at MIT's Picower Institute for Learning and Memory have corrected key symptoms of mental retardation and autism in mice. The work, which will be reported in the Dec. 20 issue of Neuron, indicates that a certain class of drugs could have the same effect in humans. These drugs are not yet approved by the FDA, but will soon be entering into clinical trials.

Asacol found effective in ulcerative colitis, proctitis
Data from two Phase III clinical trials support that Asacol, an oral, non-steroidal medication that belongs to the class of agents known as 5-aminosalicylic acids (5-ASAs), is an effective and well-tolerated treatment for patients with all extents of ulcerative colitis (UC), including isolated proctitis.

Predicting hip fracture risk in postmenopausal women
To help doctors predict the five-year risk of hip fractures in their postmenopausal patients, a team of UC Davis researchers has developed a method that assesses nearly a dozen factors, including age, ethnicity and level of physical activity.

154 Trial articles listed above.

Health Newstrack is dedicated to serve recent and updated health & medical research, events/news, views/reviews to its subscribers and free access to general public, health & medical professionals, and other health seekers worldwide online with a user-friendly system. Track health news daily at Health Newstrack.
Subscribe: rss | email

Top sections:
Health (189)
Breast cancer (169)
Healthcare (134)
HIV (130)
Obesity (126)
Pregnancy (115)
Diabetes (102)
Swine Flu (97)
Prostate Cancer (86)
Heart disease (86)
Smoking (81)
Alzheimer's Disease (79)
Cancer (75)
Depression (61)
Autism (53)

List health news, Health organizations, Health news world, Glossary     Go to top

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information, and Health News Track is hon code accredited, verify here.
About us, Site map Privacy policy, Disclaimer
© 2015
Health Newstrack - Track Health News Daily at Our Newstrack on Health News provides latest health news, medical news, and health articles with recent health & medical updates.